J&J featured image

J&J Aims to Produce a Potential Coronavirus Vaccine by April 2021

As the coronavirus pandemic infects nearly 2 million people around the world. Johnson & Johnson (J&J) plans to begin imminent production of its trial COVID-19 vaccine on an “at-risk” basis.

J&J is aiming to produce between 600 million and 900 million doses of its potential coronavirus vaccine by the end of the first quarter of 2021 if human trials are scheduled to begin in September as planned.

“We’re manufacturing at risk to ensure that should the clinical development and the trials be successful, we are in a position to kind of flip the switch and ready to go, to create great access across the globe,” J&J CFO Joe Wolk told Yahoo Finance in an interview.

During J&J’s first-quarter earnings call, Chief Scientific Officer Paul Stoffels said the company is also negotiating with partners in Europe and Asia to produce the vaccine, and partnerships will be announced in the coming weeks.

“Our goal is to enable the supply of more than 1 billion doses of the vaccine globally,” Stoffels said.

Johnson & Johnson said March 31, that it had arranged a partnership with an arm of the US Department of Health and Human Services to continue development on a vaccine. Janssen Pharmaceutical Companies, a division of J&J, will work with the BARDA, or the Biomedical Advanced Research and Development Authority, to fund and quickly test what J&J says is their leading candidate for a coronavirus vaccine.

In a statement of Alex Gorsky, CEO of Johnson & Johnson said that he and J&J were “committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible.” He said. “the world’s largest healthcare company” was “well-positioned” to help drive the fight against the pandemic.

Dr. Stoffels expressed gratitude for the government’s support. “Our teams are working tirelessly alongside BARDA, scientific partners, and global health authorities,” he said in a statement.